Total
0
Shares
PainChek (ASX:PCK)- CEO, Philip Daffas (left)
CEO, Philip Daffas (left)
Source: PainChek
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • PainChek (PCK) has received CE Mark and Therapeutic Goods Administration (TGA) clearance for its expanded PainChek app
  • The key approvals mean the app, the world’s first smart phone-based pain assessment and monitoring application, can now be sold and marketed in the U.K., Australia and Europe
  • PainChek allows carers to assess and manage pain for patients who cannot verbalise their pain, while also monitoring the effect of medication and treatment over time
  • Following the approval, PainChek will roll out in Australia and the U.K. from April 2021, before moving into mainland Europe and other overseas markets
  • PainChek shares are down 1.43 per cent, trading at 6.9 cents

PainChek (PCK) has received CE Mark and Therapeutic Goods Administration (TGA) clearance for its expanded PainChek universal app.

The company’s proprietary app, the world’s first smart phone-based pain assessment and monitoring application, has received clearances in Europe, the U.K. and Australia, allowing it to be sold and marketed internationally.

Following the key approvals, PainChek will roll out in Australia and the U.K. from April, before moving onto mainland Europe and other overseas markets.

The mobile phone app records a short video of a patient’s face and analyses the images that indicate pain. Once a caregiver has also recorded their observations of pain behaviours, the app can calculate an overall pain score and store the result, allowing the caregiver to monitor the effect of medication and treatment over time.

Based on market feedback and client demand, PainChek expanded the utility of its app to include the numeric rating scale, an established standard used to document self-reported pain levels in patients.

The combination of PainChek and the rating scale in the app allows carers to assess and manage pain for patients who cannot verbalise their pain. Due to this, the app will initially be available for adults who are unable to verbalise their pain, like dementia patients, before being offered to children who have not yet learned to speak.

The company says the app will also generate significant additional data on pain assessment outcomes and activity at individual, facility and group levels, through dashboards to provide insights to clinicians to make important medical decisions on pain management and optimum therapeutic interventions.


PainChek shares are down 1.43 per cent, trading at 6.9 cents at 9:20am AEDT.

PCK by the numbers
More From The Market Herald
(ASX:ATH) -

" Alterity Therapeutics (ASX:ATH) expands clinical development program

Alterity Therapeutics (ATH) is expanding the phase two clinical development program for its lead asset ATH434 in patients with Multiple System Atrophy (MSA).
Althea Group (ASX:AGH) - CEO, Joshua Fegan

" Althea Group (ASX:AGH) hits new high in sales receipts

Althea Group (AGH) brought in a new high of $4.5 million in customer receipts over the recently completed September quarter.
Singular Health Group (ASX:SHG) - Chief Operating Officer, James Hill

" Singular Health (ASX:SHG) collaborates with CSIRO and Osteopore (ASX:OSX)

Singular Health Group (SHG) will collaborate with CSIRO and Osteopore (OSX) for an artificial intelligence (AI) based tool to make patient-specific 3D cranial
ImpediMed (ASX:IPD) - MD and CEO, Richard Carreon

" ImpediMed (ASX:IPD) completes lymphoedema prevention trial

ImpediMed (IPD) has rounded off its PREVENT trial, successfully meeting its primary end point.